Sign in

You're signed outSign in or to get full access.

James Graf

Interim Chief Financial Officer at NKGen Biotech
Executive

About James Graf

James A. Graf serves as Interim Chief Financial Officer of NKGen Biotech, joining at the closing of the business combination on October 2, 2023 . As of late 2023, he was 59 and listed among NKGen’s executive officers; his background centers on SPAC origination and execution, having served as CEO/founder or non‑independent director across five SPACs that raised approximately $1.6B in aggregate over the prior decade, and as an independent director of another SPAC focused on technology in Southeast Asia/Australia . No education credentials or NKGen-specific TSR/revenue/EBITDA performance metrics for his tenure were disclosed in the filings reviewed.

Past Roles

OrganizationRoleYearsStrategic Impact
Graf Acquisition Corp. IVChief Executive Officer2021 onward (per IPO and transaction timeline)Led the SPAC that merged with NKGen; facilitated public listing and financing pathway .
Multiple Graf-related SPACsFounder/executive officer or non-independent directorPrior decadeAggregate $1.6B raised; extensive PIPE engagement and SPAC execution capabilities .

External Roles

OrganizationRoleYearsStrategic Impact
Graf Acquisition Partners IV LLC (Sponsor)Managing MemberPre‑merger and post‑mergerVoting/investment discretion over Sponsor’s founder shares and warrants; potential governance influence .
Unspecified Tech-focused SPAC (SE Asia/Australia)Independent DirectorNot disclosedRegional technology exposure; board oversight experience .

Fixed Compensation

No CFO-specific base salary, target bonus, or actual bonus for James Graf was disclosed in NKGen’s 2024 10‑K/A or 2025 proxy materials. NKGen’s filings detail compensation for other NEOs but do not include Graf’s CFO compensation terms .

Performance Compensation

No CFO-specific incentive plan metrics (e.g., revenue growth, EBITDA, TSR), RSU/PSU grants, or option strike/vesting schedule for James Graf were disclosed beyond options exercisable within 60 days (see ownership section). Company-wide equity plan mechanics and non‑employee director RSU treatment on change‑of‑control are described generally but not tied to Graf .

Equity Ownership & Alignment

Multi-period beneficial ownership for James A. Graf:

MetricApr 29, 2024Jan 24, 2025 (Proxy Record Date)
Beneficial ownership (# shares)7,689,577 3,108,610
Ownership % of outstanding26.76% 6.92%

Breakdown of holdings (as of Jan 24, 2025):

ComponentAmountNotes
Sponsor-held common shares (Graf Acquisition Partners IV LLC)2,082,507Graf has sole voting/investment discretion over Sponsor founder shares .
Public shares held by Graf6,800Direct holdings .
Private Warrants underlying common757,942Issued to Sponsor at IPO; held by Sponsor .
Public Warrants underlying common1,360Held directly by Graf .
Working Capital Warrants underlying common93,334Issued to Sponsor upon loan conversion; held by Sponsor .
Options exercisable within 60 days166,667NKGen options .

Pre-closing (Oct 5, 2023) disclosed “Owned Securities”:

HolderFounder SharesCovered SecuritiesPrivate Placement Warrants
Graf Acquisition Partners IV LLC (Sponsor)4,210,375 0 4,721,533
James A. Graf0 6,800 0
  • Beneficial ownership disclaimers: Graf may be deemed to share voting/dispositive power over Sponsor-held shares and disclaims beneficial ownership except to the extent of his pecuniary interest .
  • Pledging/hedging: No pledging or hedging disclosures for Graf were identified in the reviewed 10‑K/A (2024) or DEF 14A (2025) filings .

Employment Terms

  • Appointment: Joined NKGen as Interim CFO concurrent with business combination closing on Oct 2, 2023 .
  • Indemnification/D&O insurance: NKGen maintains indemnification agreements for directors/officers and D&O insurance post‑closing; these apply broadly to officers (no Graf-specific addenda disclosed) .
  • Severance/change‑of‑control: NKGen’s 10‑K/A details severance protections for the CEO but indicates other NEOs generally lack severance; no CFO-specific severance or CIC terms for Graf were disclosed . Non‑employee director RSU treatment under change‑of‑control is described, but Graf is an officer, not a non‑employee director .

Investment Implications

  • Alignment: Graf has meaningful economic exposure through Sponsor founder shares and warrants, plus personal shares and options, aligning with equity value creation; however, he disclaims beneficial ownership of Sponsor holdings beyond pecuniary interest . Near-term selling pressure could be influenced by warrant exercises and any lock-up expirations under Sponsor/Graf insider agreements, though specific durations for Graf’s lock-up were not disclosed in the cited sections .
  • Governance/related-party sensitivity: Graf’s dual role as NKGen officer and managing member of the Sponsor concentrating voting discretion may warrant investor attention to potential conflicts; the company’s related person transaction policy and indemnification framework are in place .
  • Data gaps: Absence of CFO compensation specifics (salary, bonus, vesting schedules) limits pay‑for‑performance assessment; investors should monitor future proxies/8‑Ks for detailed CFO comp, ownership changes, and any Form 4 activity.

Key disclosed facts:
• Interim CFO since Oct 2, 2023 .
• Current beneficial ownership: 3,108,610 shares (6.92%) with detailed components (sponsor shares, warrants, options) .
• Prior (Apr 29, 2024) beneficial ownership: 7,689,577 shares (26.76%) .
• Sponsor/insider lock-up and registration rights exist; definitions provided (durations not specified in cited excerpts) .